Companies ›Healthcare ›ASRT.O

ASRT.O — NASDAQ Pharmaceuticals

Assertio Holdings Inc

$23,50

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

151,7M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-25,0 %

ROE

-32,3 %

Net margin

-25,6 %

Debt / equity

0,42

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$23,46

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Assertio Holdings Inc is a specialty pharmaceutical company focused on the development, manufacturing, and commercialization of branded and generic prescription pharmaceutical products.

Business. Assertio Holdings Inc (ASRT.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

Generated · model-assisted

Sell-side consensus

HOLD4 analysts

1 buy3 hold0 sell

Avg 12m price target27,25

Analyst recommendations

4 analysts · consensus Hold

Buy1

Hold3

Sell0

12-month price target

27,25

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

4 analysts · indicative

Ownership→

Geode Capital Management, L.L.C.

largest disclosed fund holder

Profitability→

-32,3 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ASRT.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ASRT.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Assertio Holdings Inc (ASRT.O) is a pharmaceutical company operating within the Healthcare sector, specifically focused on Pharmaceuticals & Medical Research. The firm generates revenue through product sales and is primarily listed on the NASDAQ exchange. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not provided in the available data.

Classification99 %

SectorHealth Care

Industry groupPharmaceuticals

AI synthesis

GENERATED

Assertio's capital structure shows a market cap of $150.5 million with a price-to-book ratio of 1.6, indicating a moderate premium to its book value. The company holds $10.2 million in cash and equivalents but has $39.1 million in long-term debt, resulting in a debt-to-equity ratio of 0.42. Despite a current ratio of 1.7, the company's operating cash flow is negative at -$28.2 million, and free cash flow is -$0.37 million, signaling liquidity constraints.

Profitability metrics are weak, with a net loss of $30.4 million and an operating loss of $29.7 million. Return on equity is -32.3%, and return on assets is -11.4%, both significantly below industry norms for pharmaceutical firms. Gross profit of $83.3 million represents 70% of revenue, but this is insufficient to offset operating costs.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and regulatory changes. No material revenue is attributed to international operations, suggesting a U.S.-centric business model.

Outlook for the current fiscal year is negative, with a net loss expected to persist. No growth in revenue is projected for the next fiscal year, and the company is unlikely to achieve positive operating income in the near term. Historical revenue trends show a decline in performance, with no clear catalysts for reversal.

Risk factors include liquidity constraints, with negative net cash after subtracting total debt. The company has a low dilution risk, but its operating cash flow and free cash flow are insufficient to support debt servicing or growth initiatives. No recent filings or transcripts indicate material changes in strategy or operations.

Analyst sentiment is mixed, with a mean recommendation of 2.75 (1=strong buy, 5=strong sell) and a median price target of $23.00. The high price target of $45.00 is an outlier, while the low price target of $18.00 reflects pessimism about the company's near-term prospects.

Key takeaways

Assertio is a specialty pharmaceutical company with a weak profitability profile and negative returns on equity and assets.
The company's capital structure is leveraged, with a debt-to-equity ratio of 0.42 and negative net cash after debt.
Revenue is concentrated in a single segment, with no geographic diversification, increasing exposure to market-specific risks.
Analysts are cautiously neutral, with a median price target of $23.00 and no strong buy recommendations.
The company is unlikely to achieve positive operating income in the near term, with no clear growth catalysts identified.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$23,50

Market cap

$150.5M

Enterprise valueⓘ

$179.4M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

1.6x

P / Tangible bookⓘ

1.6x

Tangible book

$94.0M

Net cashⓘ

-$28.9M

Current ratioⓘ

1.7

Debt / equityⓘ

0.4

ROAⓘ

-11.4%

ROEⓘ

-32.3%

Cash conversionⓘ

93.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships12 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries12

EX21:1fd6202c9bb3EX21:1fd6202c9bb3Subsidiarie97%

EX21:24b05f1eb352EX21:24b05f1eb352Subsidiarie97%

EX21:2f89e6bf2528EX21:2f89e6bf2528Subsidiarie97%

EX21:375ab6320140EX21:375ab6320140Subsidiarie97%

EX21:52a9a1e9e3f8EX21:52a9a1e9e3f8Subsidiarie97%

EX21:5d5931ee7031EX21:5d5931ee7031Subsidiarie97%

EX21:69966556b88cEX21:69966556b88cSubsidiarie97%

EX21:6a9757bb99a4EX21:6a9757bb99a4Subsidiarie97%

EX21:6c559c51d424EX21:6c559c51d424Subsidiarie97%

EX21:7f0aeab11e31EX21:7f0aeab11e31Subsidiarie97%

EX21:91ffacfe5fabEX21:91ffacfe5fabSubsidiarie97%

EX21:f3eeec17b628EX21:f3eeec17b628Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs ASRT · multiples and returns

JNJ—

Johnson & Johnson

$254,43

622,1B USD

P/E

23,5x

— vs self

Div yield

2,0 %

— vs self

ROE

33,0 %

+65,3 vs self

LLY—

ELI LILLY AND COMPANY

$1 124,04

1,01T USD

P/E

52,0x

— vs self

Div yield

0,5 %

— vs self

ROE

66,2 %

+98,5 vs self

MRK—

MERCK & CO., INC.

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

PFE—

Pfizer Inc

$25,05

143,6B USD

P/E

18,2x

— vs self

Div yield

6,9 %

— vs self

ROE

8,6 %

+40,9 vs self

ABBV—

Abbvie Inc

$245,10

434,8B USD

P/E

110,6x

— vs self

Div yield

2,5 %

— vs self

ROE

-63,5 %

-31,2 vs self

AZN—

AZN.L

$157,59

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BMY—

Bristol-myers Squibb Co

$65,60

134,3B USD

P/E

17,7x

— vs self

Div yield

4,1 %

— vs self

ROE

31,6 %

+63,9 vs self

GSK—

Gsk Plc-spon Adr

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,17

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-16 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,17
Revenue	—no estimate	—no estimate	113,7M UNKNOWN ERROR IN UNIVERSE PROCESSING
Operating income	—no estimate	—no estimate	2,0M UNKNOWN ERROR IN UNIVERSE PROCESSING

Full-year consensus mean (period as reported by source) · consensus in UNKNOWN ERROR IN UNIVERSE PROCESSING. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution4 analysts

Strong buy0

Buy1

Hold3

Sell0

Strong sell0

12-month price target$27,25 · Median $23,00

Low $18,00High $45,00

Operating income · consensus2,0M UNKNOWN ERROR IN UNIVERSE PROCESSING

EPS surprise

−2 647,8 %

reported vs consensus · miss

Revenue surprise

+4,4 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$18,00

Mean$27,25

Median$23,00

High$45,00

Spot$23,50

+16.0 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-25,0 %Bottom quartile

Net Margin-25,6 %Bottom quartile

ROE-32,3 %Bottom quartile

D/E0,42Below median

Cash Conv0,93Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 360 975 sh6 exercises · 7 grants9 insiders

Reisenauer Mark LDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 66 666 @ $12,37disposition · 2026-06-16
MCKEE WILLIAMDirector · Stock Option (Right to Buy) → Common StockDisposed 5 415 @ $15,15disposition · 2026-06-16
Schlessinger SamEVP, General Counsel · Restricted Stock Units → Common StockDisposed 25 748disposition · 2026-06-16
Schlessinger SamEVP, General Counsel · Stock Option (Right to Buy) → Common StockDisposed 15 666 @ $19,65disposition · 2026-06-16
Schlessinger SamEVP, General Counsel · Stock Option (Right to Buy) → Common StockDisposed 18 900 @ $11,90disposition · 2026-06-16
Schlessinger SamEVP, General Counsel · Stock Option (Right to Buy) → Common StockDisposed 12 591 @ $12,18disposition · 2026-06-16
Schlessinger SamEVP, General Counsel · Stock Option (Right to Buy) → Common StockDisposed 21 128 @ $11,77disposition · 2026-06-16
Kirk SigurdDirector · Stock Option (Right to Buy) → Common StockDisposed 7 913 @ $17,10disposition · 2026-06-16
Kirk SigurdDirector · Stock Option (Right to Buy) → Common StockDisposed 5 415 @ $15,15disposition · 2026-06-16
Emany Sravan KumarDirector · Stock Option (Right to Buy) → Common StockDisposed 1 753 @ $16,05disposition · 2026-06-16
Emany Sravan KumarDirector · Stock Option (Right to Buy) → Common StockDisposed 5 415 @ $15,15disposition · 2026-06-16
Schwichtenberg PaulPresident and COO · Restricted Stock Units → Common StockDisposed 32 042disposition · 2026-06-16
Schwichtenberg PaulPresident and COO · Stock Option (Right to Buy) → Common StockDisposed 15 666 @ $19,65disposition · 2026-06-16
Schwichtenberg PaulPresident and COO · Stock Option (Right to Buy) → Common StockDisposed 22 666 @ $11,90disposition · 2026-06-16
Schwichtenberg PaulPresident and COO · Stock Option (Right to Buy) → Common StockDisposed 12 591 @ $12,18disposition · 2026-06-16
Schwichtenberg PaulPresident and COO · Stock Option (Right to Buy) → Common StockDisposed 27 888 @ $11,77disposition · 2026-06-16
Reisenauer Mark LDirector, CEO · Restricted Stock Units → Common StockDisposed 33 333disposition · 2026-06-16
Reisenauer Mark LDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 5 415 @ $12,75disposition · 2026-06-16
Patel AjayEVP and CFO · Restricted Stock Units → Common StockDisposed 26 026disposition · 2026-06-16
Patel AjayEVP and CFO · Stock Option (Right to Buy) → Common StockDisposed 15 666 @ $19,65disposition · 2026-06-16
Patel AjayEVP and CFO · Stock Option (Right to Buy) → Common StockDisposed 22 666 @ $11,90disposition · 2026-06-16
Patel AjayEVP and CFO · Stock Option (Right to Buy) → Common StockDisposed 12 591 @ $12,18disposition · 2026-06-16
Patel AjayEVP and CFO · Stock Option (Right to Buy) → Common StockDisposed 21 128 @ $11,77disposition · 2026-06-16
Reisenauer Mark LDirector, CEO · Stock Option (Right to Buy) → Common StockDisposed 26 667 @ $11,77disposition · 2026-06-16
Mason Heather LDirector · Stock Option (Right to Buy) → Common StockDisposed 36 666 @ $17,10disposition · 2026-06-16

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

Assertio Holdings Inc Market data — financials · 2026-05-27
Assertio Holdings Inc Market data — analyst estimates · 2026-05-27
Assertio Holdings Inc Market data — ESG · 2026-05-27

Ownership & reference

Top holders

Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$1M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$3M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$2M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

Insider activity

Mixed / flat0 buys · 0 sellsnet $09 insiders · last 365d

Kirk SigurdDirector · Common StockOther 12 017 · 2026-06-16
MCKEE WILLIAMDirector · Common StockOther 27 936 · 2026-06-16
Schlessinger SamEVP, General Counsel · Common StockOther 14 738 · 2026-06-16
Emany Sravan KumarDirector · Common StockOther 23 855 · 2026-06-16
Schwichtenberg PaulPresident and COO · Common StockOther 13 987 · 2026-06-16
Reisenauer Mark LDirector, CEO · Common StockOther 3 583 · 2026-06-16
Mason Heather LDirector · Common StockOther 20 944 · 2026-06-16
Mason Heather LDirector · Common StockOther 6 666 · 2026-06-16
Stark David MatthewDirector · Common StockOther 11 420 · 2026-06-16
Patel AjayEVP and CFO · Common StockOther 15 942 · 2026-06-16
Mason Heather LDirector · Common StockOther 6 666 · 2026-05-13
Mason Heather LDirector · Common StockOther 4 851 · 2026-05-05
Stark David MatthewDirector · Common StockOther 4 851 · 2026-05-05
Emany Sravan KumarDirector · Common StockOther 4 851 · 2026-05-05
Kirk SigurdDirector · Common StockOther 4 851 · 2026-05-05
MCKEE WILLIAMDirector · Common StockOther 4 851 · 2026-05-05
Patel AjayEVP and CFO · Common StockOther 566 @ $11,84$7K · 2026-02-21
Schwichtenberg PaulPresident and COO · Common StockOther 566 @ $11,84$7K · 2026-02-21
Schlessinger SamEVP, General Counsel · Common StockOther 1 143 · 2026-02-21
Schlessinger SamEVP, General Counsel · Common StockOther 510 @ $11,84$6K · 2026-02-21
Patel AjayEVP and CFO · Common StockOther 1 143 · 2026-02-21
Schwichtenberg PaulPresident and COO · Common StockOther 1 143 · 2026-02-21
Patel AjayEVP and CFO · Common StockOther 1 377 @ $11,87$16K · 2026-02-18
Schlessinger SamEVP, General Counsel · Common StockOther 1 239 @ $11,87$15K · 2026-02-18
Schwichtenberg PaulPresident and COO · Common StockOther 2 778 · 2026-02-18

Short positioning

156.3Kshares short-53.3% vs prior

1days to cover

73.2%short of daily vol

1.9Kfails-to-deliver

as of 2026-06-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ASRT.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Net income (YoY) (2025-12-31 vs 2024-12-31): -40.7%Derived (calculated)
Net margin (FY 2025-12-31): -25.6%Derived (calculated)
Return on equity (FY 2025-12-31): -32.3%Derived (calculated)
Return on assets (FY 2025-12-31): -11.4%Derived (calculated)
Current ratio (FY 2025-12-31): 1.70xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 1.84xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -79.8%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -39.4%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -39.4%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 0.8%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -206.7%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 12.0%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -22.4%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -6.2%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 5.7%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -55.8%Derived (calculated)
Cash & equivalents (annual): USD 10.23MSEC XBRL filing
Total liabilities (annual): USD 173.02MSEC XBRL filing
Revenue (annual): USD 118.71MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES -5SEC XBRL filing
Pre-tax income (annual): USD -29.94MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -5SEC XBRL filing
Total assets (annual): USD 266.97MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-16 00:00 UTCINSIDER37 insider transactions — 2026-06 27 derivative

2026-06-16FILINGFORM 8-K →

2026-06-16INSIDERKirk Sigurd transacted 12.0k sh — Director

2026-06-16INSIDERMCKEE WILLIAM transacted 27.9k sh — Director

2026-06-16INSIDERSchlessinger Sam transacted 14.7k sh — EVP, General Counsel

2026-06-16INSIDEREmany Sravan Kumar transacted 23.9k sh — Director

2026-06-16INSIDERSchwichtenberg Paul transacted 14.0k sh — President and COO

2026-06-16INSIDERReisenauer Mark L transacted 3.6k sh — Director, CEO

2026-06-16INSIDERMason Heather L transacted 20.9k sh — Director

2026-06-16INSIDERMason Heather L transacted 6.7k sh — Director

2026-06-16INSIDERStark David Matthew transacted 11.4k sh — Director

2026-06-16INSIDERPatel Ajay transacted 15.9k sh — EVP and CFO

2026-06-16INSIDERKirk Sigurd disposed of 5.4k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDERMCKEE WILLIAM disposed of 5.4k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDERSchlessinger Sam disposed of 25.7k sh Restricted Stock Units — EVP, General Counsel

2026-06-16INSIDERSchlessinger Sam disposed of 15.7k sh Stock Option (Right to Buy) — EVP, General Counsel

2026-06-16INSIDERSchlessinger Sam disposed of 18.9k sh Stock Option (Right to Buy) — EVP, General Counsel

2026-06-16INSIDERSchlessinger Sam disposed of 12.6k sh Stock Option (Right to Buy) — EVP, General Counsel

2026-06-16INSIDERSchlessinger Sam disposed of 21.1k sh Stock Option (Right to Buy) — EVP, General Counsel

2026-06-16INSIDERKirk Sigurd disposed of 7.9k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDEREmany Sravan Kumar disposed of 1.8k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDEREmany Sravan Kumar disposed of 5.4k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDERSchwichtenberg Paul disposed of 32.0k sh Restricted Stock Units — President and COO

2026-06-16INSIDERSchwichtenberg Paul disposed of 15.7k sh Stock Option (Right to Buy) — President and COO

2026-06-16INSIDERSchwichtenberg Paul disposed of 22.7k sh Stock Option (Right to Buy) — President and COO

2026-06-16INSIDERSchwichtenberg Paul disposed of 12.6k sh Stock Option (Right to Buy) — President and COO

2026-06-16INSIDERSchwichtenberg Paul disposed of 27.9k sh Stock Option (Right to Buy) — President and COO

2026-06-16INSIDERReisenauer Mark L disposed of 33.3k sh Restricted Stock Units — Director, CEO

2026-06-16INSIDERReisenauer Mark L disposed of 5.4k sh Stock Option (Right to Buy) — Director, CEO

2026-06-16INSIDERReisenauer Mark L disposed of 66.7k sh Stock Option (Right to Buy) — Director, CEO

2026-06-16INSIDERPatel Ajay disposed of 26.0k sh Restricted Stock Units — EVP and CFO

2026-06-16INSIDERMason Heather L disposed of 5.4k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDERStark David Matthew disposed of 5.4k sh Stock Option (Right to Buy) — Director

2026-06-16INSIDERPatel Ajay disposed of 21.1k sh Stock Option (Right to Buy) — EVP and CFO

2026-06-16INSIDERPatel Ajay disposed of 12.6k sh Stock Option (Right to Buy) — EVP and CFO

2026-06-16INSIDERPatel Ajay disposed of 22.7k sh Stock Option (Right to Buy) — EVP and CFO

2026-06-16INSIDERPatel Ajay disposed of 15.7k sh Stock Option (Right to Buy) — EVP and CFO

2026-05-18FILINGFORM 8-K →

Showing the 40 most recent of 58 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread